T1	PROC 44 74	Estudio aleatorizado y abierto
T2	PROC 80 114	evaluar la seguridad y la eficacia
#1	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
T3	CHEM 170 180	ribavirina
#2	AnnotatorNotes T3	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	CHEM 182 185	RBV
#3	AnnotatorNotes T4	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	DISO 202 250	infección crónica por el virus de la hepatitis C
#4	AnnotatorNotes T5	C4736230; chronic hepatitis C due to hepatitis C virus genotype 1a; Disease or Syndrome | C4736234; chronic hepatitis C due to hepatitis C virus genotype 4; Disease or Syndrome
T6	DISO 278 286	cirrosis
#5	AnnotatorNotes T6	C1623038; Cirrhosis; Disease or Syndrome
T7	CHEM 118 128	Ombitasvir
#6	AnnotatorNotes T7	C3852670; ombitasvir; Organic Chemical · Pharmacologic Substance
T8	DISO 319 344	Infección por Hepatitis C
T9	CHEM 137 146	Ritonavir
#7	AnnotatorNotes T9	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T10	PROC 495 516	tratamiento antiviral
#8	AnnotatorNotes T10	C2363964; Antiviral treatment; Therapeutic or Preventive Procedure
T11	DISO 525 542	infección por VHC
T12	PROC 714 742	niveles de ARN VHC en plasma
T13	CHEM 637 640	IFN
#9	AnnotatorNotes T13	C0021747; Interferons; Amino Acid, Peptide, or Protein · Immunologic Factor
T14	CHEM 641 644	RBV
#10	AnnotatorNotes T14	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T15	DISO 649 666	Infección por VHC
T16	DISO 690 698	cirrosis
#11	AnnotatorNotes T16	C1623038; Cirrhosis; Disease or Syndrome
T17	CHEM 725 728	ARN
#12	AnnotatorNotes T17	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T18	ANAT 736 742	plasma
#13	AnnotatorNotes T18	C0032105; Plasma; Body Substance
T19	CHEM 833 836	SOF
#14	AnnotatorNotes T19	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T20	PROC 456 462	tratar
#15	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	CHEM 844 847	RBV
#16	AnnotatorNotes T21	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T22	CHEM 854 857	RBV
#17	AnnotatorNotes T22	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T23	CHEM 943 946	ARN
#18	AnnotatorNotes T23	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T24	PROC 979 990	tratamiento
#19	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	CHEM 1006 1009	RBV
#20	AnnotatorNotes T25	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T26	CHEM 1016 1019	RBV
#21	AnnotatorNotes T26	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T27	CHEM 1049 1052	ARN
#22	AnnotatorNotes T27	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T28	PROC 1091 1102	tratamiento
#23	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	CHEM 1114 1117	RBV
#24	AnnotatorNotes T29	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T30	CHEM 1124 1127	RBV
#25	AnnotatorNotes T30	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T31	PROC 809 816	tratado
#26	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	PROC 1175 1186	seguimiento
#27	AnnotatorNotes T32	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T33	PROC 1268 1319	prueba del antígeno de superficie de la hepatitis B
T34	CHEM 1279 1319	antígeno de superficie de la hepatitis B
#28	AnnotatorNotes T34	C0019168; Hepatitis B Surface Antigens; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	PROC 1321 1326	HBsAg
#29	AnnotatorNotes T35	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T36	PROC 1335 1393	anticuerpos contra el virus de la inmunodeficiencia humana
#30	AnnotatorNotes T36	C3714540; HIV Antibody Measurement; Laboratory Procedure
T37	PROC 1395 1401	Ac VIH
T38	PROC 1434 1466	estudio clínico intervencionista
T39	CHEM 1012 1015	SOF
#31	AnnotatorNotes T39	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T40	CHEM 1529 1555	inhibidores de la proteasa
#32	AnnotatorNotes T40	C0033607; Protease Inhibitors; Pharmacologic Substance
T41	CHEM 1557 1602	inhibidores de la polimerasa no nucleosídicos
T42	CHEM 1707 1714	ABT-450
#33	AnnotatorNotes T42	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T43	CHEM 1719 1729	ombitasvir
#34	AnnotatorNotes T43	C3852670; ombitasvir; Organic Chemical · Pharmacologic Substance
T44	CHEM 1605 1627	inhibidores de la NS5A
T45	PROC 1049 1060	ARN del VHC
#35	AnnotatorNotes T45	C1272251; Hepatitis C virus RNA assay; Laboratory Procedure
T46	CHEM 1837 1847	medicación
#36	AnnotatorNotes T46	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T47	PROC 943 954	ARN del VHC
#37	AnnotatorNotes T47	C1272251; Hepatitis C virus RNA assay; Laboratory Procedure
T48	CHEM 1904 1931	antiviral de acción directa
T49	CHEM 2055 2061	pegIFN
#38	AnnotatorNotes T49	C0907160; Pegylated Interferon Alfa; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T50	CHEM 1999 2038	inhibidor de la polimerasa nucleosídico
T51	CHEM 2040 2050	Sofosbuvir
#39	AnnotatorNotes T51	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T52	CHEM 2064 2067	RBV
#40	AnnotatorNotes T52	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T53	CHEM 2070 2073	RBV
#41	AnnotatorNotes T53	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T54	DISO 2175 2199	descompensación hepática
#42	AnnotatorNotes T54	C0085605; Liver Failure; Disease or Syndrome | C1394798; Hepatic decompensation; Pathologic Function
T55	DISO 2206 2213	ascitis
#43	AnnotatorNotes T55	C0003962; Ascites; Disease or Syndrome
T56	DISO 2215 2233	varices esofágicas
#44	AnnotatorNotes T56	C0014867; Esophageal Varices; Disease or Syndrome
T57	DISO 2236 2258	encefalopatía hepática
#45	AnnotatorNotes T57	C0019151; Hepatic Encephalopathy; Disease or Syndrome
T58	CHEM 995 998	SOF
#46	AnnotatorNotes T58	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T59	DISO 2286 2309	carcinoma hepatocelular
#47	AnnotatorNotes T59	C2239176; Liver carcinoma; Neoplastic Process
T60	DISO 2332 2351	enfermedad hepática
#48	AnnotatorNotes T60	C0023895; Liver diseases; Disease or Syndrome
T61	DISO 2367 2395	infección crónica por el VHC
T62	CHEM 850 853	SOF
#49	AnnotatorNotes T62	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T63	DISO 252 255	VHC
#50	AnnotatorNotes T63	C0019196; Hepatitis C; Disease or Syndrome
T64	CHEM 507 516	antiviral
#51	AnnotatorNotes T64	C0003451; Antiviral Agents; Pharmacologic Substance
T65	CHEM 129 136	ABT-450
#52	AnnotatorNotes T65	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T66	CHEM 938 941	SOF
#53	AnnotatorNotes T66	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T67	CHEM 1041 1044	SOF
#54	AnnotatorNotes T67	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T68	CHEM 1107 1113	pegIFN
#55	AnnotatorNotes T68	C0907160; Pegylated Interferon Alfa; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T69	CHEM 1120 1123	SOF
#56	AnnotatorNotes T69	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T70	CHEM 837 843	pegIFN
#57	AnnotatorNotes T70	C0907160; Pegylated Interferon Alfa; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T71	CHEM 1103 1106	SOF
#58	AnnotatorNotes T71	C2976303; sofosbuvir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T72	PROC 1816 1847	administración de la medicación
T73	CHEM 999 1005	pegIFN
#59	AnnotatorNotes T73	C0907160; Pegylated Interferon Alfa; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T74	ANAT 2191 2199	hepática
#60	AnnotatorNotes T74	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T75	ANAT 2223 2233	esofágicas
#61	AnnotatorNotes T75	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T76	ANAT 2250 2258	hepática
#62	AnnotatorNotes T76	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T77	ANAT 2296 2309	hepatocelular
#63	AnnotatorNotes T77	C0227525; Hepatocyte; Cell
T78	ANAT 2343 2351	hepática
#64	AnnotatorNotes T78	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T79	PROC 2398 2416	Pruebas analíticas
T80	Date 12 16	2014
T81	LIVB 190 197	adultos
#65	AnnotatorNotes T81	C0001675; Adult; Age Group
T82	Duration 212 219	crónica
#66	AnnotatorNotes T82	C0205191; chronic; Temporal Concept
T83	LIVB 227 250	virus de la hepatitis C
#67	AnnotatorNotes T83	C0220847; hepatitis C virus; Virus
T85	PROC 261 269	genotipo
#68	AnnotatorNotes T85	C1285573; Genotype determination; Laboratory Procedure
T86	LIVB 390 399	pacientes
#69	AnnotatorNotes T86	C0030705; Patients; Patient or Disabled Group
T88	LIVB 442 451	Pacientes
#70	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	Neg_cue 452 455	sin
T90	LIVB 464 473	Pacientes
#71	AnnotatorNotes T90	C0030705; Patients; Patient or Disabled Group
T91	Neg_cue 478 483	nunca
T92	LIVB 539 542	VHC
#72	AnnotatorNotes T92	C0220847; hepatitis C virus; Virus
T93	LIVB 547 556	Pacientes
#73	AnnotatorNotes T93	C0030705; Patients; Patient or Disabled Group
T95	LIVB 663 666	VHC
#74	AnnotatorNotes T95	C0220847; hepatitis C virus; Virus
T96	PROC 667 675	genotipo
#75	AnnotatorNotes T96	C1285573; Genotype determination; Laboratory Procedure
T97	Duration 678 685	crónico
#76	AnnotatorNotes T97	C0205191; chronic; Temporal Concept
T98	LIVB 701 709	Paciente
#77	AnnotatorNotes T98	C0030705; Patients; Patient or Disabled Group
T99	LIVB 729 732	VHC
#78	AnnotatorNotes T99	C0220847; hepatitis C virus; Virus
T100	LIVB 784 792	paciente
#79	AnnotatorNotes T100	C0030705; Patients; Patient or Disabled Group
T102	LIVB 951 954	VHC
#80	AnnotatorNotes T102	C0220847; hepatitis C virus; Virus
T103	LIVB 1057 1060	VHC
#81	AnnotatorNotes T103	C0220847; hepatitis C virus; Virus
T104	Duration 1148 1171	las primeras 52 semanas
T105	LIVB 1357 1393	virus de la inmunodeficiencia humana
#82	AnnotatorNotes T105	C0019682; HIV; Virus
T106	LIVB 1398 1401	VIH
#83	AnnotatorNotes T106	C0019682; HIV; Virus
T107	Date 1419 1425	actual
T109	Duration 1786 1799	las 6 semanas
T110	Neg_cue 1861 1863	No
T112	Date 2092 2100	actuales
T113	Date 2103 2110	pasados
T114	Duration 2377 2384	crónica
#84	AnnotatorNotes T114	C0205191; chronic; Temporal Concept
T115	LIVB 2392 2395	VHC
#85	AnnotatorNotes T115	C0220847; hepatitis C virus; Virus
T84	PROC 2131 2141	Child-Pugh
#86	AnnotatorNotes T84	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
T87	Neg_cue 2352 2363	distinta de
T94	CHEM 1757 1782	producto en investigación
#87	AnnotatorNotes T94	C0013230; Investigational New Drugs; Pharmacologic Substance
T101	DISO 1030 1038	recidiva
#88	AnnotatorNotes T101	C2825055; Recurrence (disease attribute); Pathologic Function
T108	DISO 911 918	recaída
#89	AnnotatorNotes T108	C3160896; Hepatitis C relapse; Disease or Syndrome
A1	Population_data T81 Age
A2	Assertion T20 Negated
A3	Assertion T10 Negated
A4	Assertion T64 Negated
A5	Assertion T48 Negated
A6	Assertion T61 Negated
A7	Status T54 History_of
A8	Status T55 History_of
A9	Status T56 History_of
A10	Status T57 History_of
A11	Assertion T115 Negated
A12	Status T48 History_of
A13	Status T50 History_of
A14	Status T51 History_of
A15	Status T49 History_of
A16	Status T52 History_of
A17	Status T53 History_of
A18	Status T101 History_of
A19	Status T108 History_of
A20	Status T31 History_of
A21	Status T19 History_of
A22	Status T70 History_of
A23	Status T21 History_of
A24	Status T62 History_of
A25	Status T22 History_of
A26	Status T10 History_of
A27	Status T64 History_of
A28	Status T40 History_of
A29	Status T41 History_of
A30	Status T44 History_of
A31	Status T42 History_of
A32	Status T43 History_of
#90	AnnotatorNotes T1	C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#91	AnnotatorNotes T8	C0019196; Hepatitis C; Disease or Syndrome
#92	AnnotatorNotes T11	C0019196; Hepatitis C; Disease or Syndrome
#93	AnnotatorNotes T15	C0019196; Hepatitis C; Disease or Syndrome
#94	AnnotatorNotes T33	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
#95	AnnotatorNotes T37	C3714540; HIV Antibody Measurement; Laboratory Procedure
#96	AnnotatorNotes T38	C0184661; Interventional procedure; Therapeutic or Preventive Procedure + C0008976; Clinical Trials; Research Activity
#97	AnnotatorNotes T107	C0521116; Current (present time); Temporal Concept 
#98	AnnotatorNotes T112	C0521116; Current (present time); Temporal Concept 
#99	AnnotatorNotes T72	C3469597; Administration of medication; Therapeutic or Preventive Procedure
#100	AnnotatorNotes T61	C0524910; Hepatitis C, Chronic; Disease or Syndrome 
#101	AnnotatorNotes T113	C1444637; In the past; Temporal Concept 
T111	Neg_cue 919 921	no
T116	Observation 922 935	respondedores
A33	Assertion T116 Negated
#102	AnnotatorNotes T116	C0919876; Therapy responder; Finding
T117	Quantifier_or_Qualifier 1589 1602	nucleosídicos
A34	Assertion T117 Negated
T118	Neg_cue 1586 1588	no
R1	Negation Arg1:T89 Arg2:T20	
R2	Negation Arg1:T91 Arg2:T10	
R3	Negation Arg1:T91 Arg2:T64	
R4	Used_for Arg1:T64 Arg2:T10	
R5	Negation Arg1:T111 Arg2:T116	
R6	Negation Arg1:T118 Arg2:T117	
R7	Negation Arg1:T110 Arg2:T48	
R8	Negation Arg1:T87 Arg2:T61	
R9	Combined_with Arg1:T7 Arg2:T65	
R10	Combined_with Arg1:T65 Arg2:T9	
R11	Combined_with Arg1:T9 Arg2:T3	
R12	Combined_with Arg1:T9 Arg2:T4	
R13	Experiences Arg1:T81 Arg2:T7	
R14	Experiences Arg1:T81 Arg2:T5	
R15	Has_Duration_or_Interval Arg1:T5 Arg2:T82	
R16	Causes Arg1:T83 Arg2:T5	
R17	Experiences Arg1:T81 Arg2:T63	
R18	Overlap Arg1:T63 Arg2:T6	
R19	Overlap Arg1:T5 Arg2:T6	
T119	Quantifier_or_Qualifier 261 271	genotipo 4
R20	Has_Quantifier_or_Qualifier Arg1:T63 Arg2:T119	
R21	Experiences Arg1:T81 Arg2:T85	
R22	Experiences Arg1:T81 Arg2:T6	
R25	Experiences Arg1:T88 Arg2:T20	
R26	Experiences Arg1:T90 Arg2:T20	
R27	Experiences Arg1:T90 Arg2:T10	
R28	Experiences Arg1:T90 Arg2:T11	
R29	Causes Arg1:T92 Arg2:T11	
R30	Used_for Arg1:T64 Arg2:T20	
T120	Observation 573 587	Respuesta nula
#103	AnnotatorNotes T120	C0438286; Absent response to treatment; Finding
R31	Experiences Arg1:T93 Arg2:T120	
A35	Status T120 History_of
T121	Observation 598 621	Respondedores parciales
#104	AnnotatorNotes T121	C1521726; partial response; Finding
R32	Experiences Arg1:T93 Arg2:T121	
T122	DISO 624 634	Recayentes
#105	AnnotatorNotes T122	C3160896; Hepatitis C relapse; Disease or Syndrome
R33	Experiences Arg1:T93 Arg2:T122	
R35	Combined_with Arg1:T13 Arg2:T14	
R37	Experiences Arg1:T93 Arg2:T13	
R39	Causes Arg1:T95 Arg2:T15	
R41	Overlap Arg1:T15 Arg2:T16	
T123	Quantifier_or_Qualifier 667 677	genotipo 4
R42	Has_Quantifier_or_Qualifier Arg1:T95 Arg2:T123	
R43	Has_Duration_or_Interval Arg1:T15 Arg2:T97	
R46	Overlap Arg1:T116 Arg2:T66	
R47	Experiences Arg1:T98 Arg2:T12	
R48	Location_of Arg1:T18 Arg2:T12	
#106	AnnotatorNotes T12	C5166375; HCV RNA Pnl | Serum or Plasma | Microbiology Panels; Laboratory Procedure
T124	Result_or_Value 743 755	>1.000 IU/ML
R49	Has_Result_or_Value Arg1:T12 Arg2:T124	
T125	PROC 759 768	Selección
#107	AnnotatorNotes T125	C0242802; Patient Selection; Research Activity
R50	Overlap Arg1:T12 Arg2:T125	
R51	Experiences Arg1:T100 Arg2:T31	
R52	Used_for Arg1:T19 Arg2:T31	
R53	Combined_with Arg1:T19 Arg2:T70	
R54	Combined_with Arg1:T70 Arg2:T21	
R55	Combined_with Arg1:T62 Arg2:T22	
R56	Used_for Arg1:T62 Arg2:T31	
T126	CONC 969 990	final del tratamiento
R57	Overlap Arg1:T47 Arg2:T126	
T127	Observation 955 965	detectable
#108	AnnotatorNotes T127	C0442726; Detected (finding); Finding
R58	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T127	
R59	Overlap Arg1:T127 Arg2:T126	
R60	Used_for Arg1:T58 Arg2:T24	
R61	Combined_with Arg1:T58 Arg2:T73	
R62	Combined_with Arg1:T73 Arg2:T25	
R63	Combined_with Arg1:T39 Arg2:T26	
R64	Used_for Arg1:T39 Arg2:T24	
R65	Overlap Arg1:T116 Arg2:T58	
R66	Overlap Arg1:T116 Arg2:T39	
T128	CONC 1081 1102	final del tratamiento
T129	Result_or_Value 1065 1077	indetectable
#109	AnnotatorNotes T129	C3827727; Undetectable; Clinical Attribute
R69	Has_Result_or_Value Arg1:T45 Arg2:T129	
R70	Overlap Arg1:T45 Arg2:T128	
R71	Used_for Arg1:T71 Arg2:T28	
R72	Combined_with Arg1:T71 Arg2:T68	
R73	Combined_with Arg1:T68 Arg2:T29	
R74	Used_for Arg1:T69 Arg2:T28	
R75	Combined_with Arg1:T69 Arg2:T30	
T130	Observation 1134 1144	se detectó
#110	AnnotatorNotes T130	C0442726; Detected (finding); Finding
R76	Overlap Arg1:T130 Arg2:T104	
R77	Has_Duration_or_Interval Arg1:T32 Arg2:T104	
R78	Overlap Arg1:T101 Arg2:T130	
R79	Before Arg1:T28 Arg2:T32	
R80	Overlap Arg1:T45 Arg2:T32	
T131	Result_or_Value 1216 1234	Resultado positivo
#111	AnnotatorNotes T131	C1446409; Positive; Finding
R82	Has_Result_or_Value Arg1:T33 Arg2:T131	
R83	Has_Result_or_Value Arg1:T35 Arg2:T131	
R84	Has_Result_or_Value Arg1:T36 Arg2:T131	
R85	Has_Result_or_Value Arg1:T37 Arg2:T131	
T132	PROC 1252 1261	selección
#112	AnnotatorNotes T132	C0242802; Patient Selection; Research Activity
R86	Overlap Arg1:T131 Arg2:T132	
R87	Overlap Arg1:T132 Arg2:T33	
R88	Overlap Arg1:T132 Arg2:T35	
R89	Overlap Arg1:T132 Arg2:T36	
R90	Overlap Arg1:T132 Arg2:T37	
R91	Causes Arg1:T34 Arg2:T131	
R92	Causes Arg1:T105 Arg2:T131	
R93	Causes Arg1:T106 Arg2:T131	
T133	Observation 1405 1418;1426 1466	Participación en otro estudio clínico intervencionista
T134	Observation 1468 1481;1491 1512	participación en este mismo estudio
A36	Status T134 History_of
#114	AnnotatorNotes T44	C3883357; Hepatitis C Virus NS5A Inhibitor; Pharmacologic Substance
R94	Overlap Arg1:T133 Arg2:T107	
R95	Overlap Arg1:T38 Arg2:T107	
R96	Overlap Arg1:T94 Arg2:T109	
R97	Before Arg1:T94 Arg2:T72	
R98	Before Arg1:T44 Arg2:T72	
R99	Used_for Arg1:T46 Arg2:T72	
R100	Before Arg1:T41 Arg2:T72	
R101	Before Arg1:T40 Arg2:T72	
R102	Before Arg1:T42 Arg2:T72	
R103	Before Arg1:T43 Arg2:T72	
#115	AnnotatorNotes T48	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
R104	Combined_with Arg1:T51 Arg2:T49	
R105	Combined_with Arg1:T51 Arg2:T53	
R106	Combined_with Arg1:T49 Arg2:T52	
T135	CONC 2077 2091	Datos clínicos
#116	AnnotatorNotes T135	C1516606; Clinical Data; Intellectual Product
R107	Overlap Arg1:T135 Arg2:T112	
R108	Overlap Arg1:T135 Arg2:T113	
A37	Status T84 History_of
R109	Overlap Arg1:T84 Arg2:T113	
R110	Overlap Arg1:T84 Arg2:T112	
T136	Result_or_Value 2142 2147	B o C
R111	Has_Result_or_Value Arg1:T84 Arg2:T136	
R112	Location_of Arg1:T74 Arg2:T54	
R113	Location_of Arg1:T75 Arg2:T56	
R114	Location_of Arg1:T76 Arg2:T57	
R115	Location_of Arg1:T77 Arg2:T59	
R116	Location_of Arg1:T78 Arg2:T60	
R117	Causes Arg1:T115 Arg2:T61	
R118	Has_Duration_or_Interval Arg1:T61 Arg2:T114	
#117	AnnotatorNotes T79	C0022885; Laboratory Procedures; Laboratory Procedure
T137	Observation 2398 2426	Pruebas analíticas anormales
#118	AnnotatorNotes T137	C3648370; laboratory tests nonspecific abnormal findings; Finding
R38	Overlap Arg1:T120 Arg2:T13	
R120	Overlap Arg1:T120 Arg2:T14	
R121	Overlap Arg1:T121 Arg2:T13	
R122	Overlap Arg1:T121 Arg2:T14	
R23	Experiences Arg1:T88 Arg2:T10	
R24	Experiences Arg1:T88 Arg2:T11	
A38	Experiencer T81 Patient
A39	Experiencer T86 Patient
A40	Experiencer T90 Patient
A41	Experiencer T88 Patient
A42	Experiencer T93 Patient
A43	Experiencer T98 Patient
A44	Experiencer T100 Patient
R34	Has_Result_or_Value Arg1:T79 Arg2:T137	
